IP Library Granted Patent US 10,101,339
Granted Patent B2
US 10,101,339 · App. 15/191,632 · Granted Oct 16, 2018

Methods and compositions for wound treatment

Inventors: John Dresios (Carlsbad, CA); Richard Griffey (Vista, CA)
Assignee: Leidos, Inc.
G01N33/6887A61K9/1271A61K38/02A61K39/44A61K47/42A61K49/0058C07K16/18G01N33/5088G01N33/567G01N33/6893A61K38/1777A61K47/6801A61K47/6803A61K47/6811A61K47/6847G01N2333/47G01N2333/4712G01N2333/78
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,101,339
App. No.
15/191,632
Granted
Oct 16, 2018
Kind
B2
Abstract

The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.

Claims (22)

1. A method for identifying a wound target for facilitating delivery of a hemostatic agent to a wound, wherein the wound target is an exposed protein, peptide motif or epitope, wherein the exposed protein, peptide motif or epitope becomes exposed upon wounding, the method comprising:

removing predetermined internal organ tissue from a mammalian subject, the predetermined internal organ tissue being selected from the group consisting of esophagus, stomach, small and large intestines, pancreas, liver, kidney, bladder, urethra, heart, lung, brain, and reproductive organs;

wounding the removed predetermined internal organ tissue to expose one or more proteins, peptide motifs or epitopes, wherein the one or more proteins, peptide motifs or epitopes are not exposed in unwounded predetermined internal organ tissue and further wherein the one or more proteins, peptide motifs or epitopes are selected from the group consisting of actin, and a cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope;

incubating the wounded predetermined internal organ tissue with a preselected detectable wound targeting moiety;

washing away unbound wound targeting moiety from the wounded predetermined internal organ tissue after a predetermined incubation period;

detecting whether the wound targeting moiety is specifically bound to an exposed protein, peptide motif or epitope; and

identifying the exposed protein, peptide motif or epitope specifically bound to the wound targeting moiety upon wounding as the wound target; wherein the detectable wound targeting moiety is a detectable antibody specifically binding to said actin or said RGD epitope.

2. The method of claim 1 , wherein the wound targeting moiety is a fluorescently labeled antibody.

3. The method of claim 1 , wherein the antibody is an antibody to actin protein.

4. The method of claim 1 , wherein identifying the exposed protein, peptide motif or epitope specifically bound upon wounding as a wound target further includes determining that the wound targeting moiety does not bind appreciably above predetermined background levels to unwounded tissue.

5. The method of claim 1 , wherein the exposed protein, peptide motif or epitope is a cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope.

6. A method for identifying a wound target for facilitating delivery of a hemostatic agent to a wound, wherein the wound target is an exposed protein, peptide motif or epitope, the method comprising:

removing predetermined internal organ tissue from a mammalian subject, the predetermined internal organ tissue being selected from the group consisting of esophagus, stomach, small and large intestines, pancreas, liver, kidney, bladder, urethra, heart, lung, brain, and reproductive organs;

wounding the removed predetermined internal organ tissue to expose a first protein, peptide motif or epitope, wherein the first protein, peptide motif or epitope is not exposed in unwounded predetermined internal organ tissue and further wherein the first protein, peptide motif or epitope is selected from the group consisting of actin, and a cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope;

incubating the wounded predetermined internal organ tissue with a first preselected detectable wound targeting moiety; wherein the first preselected detectable wound targeting moiety is a detectable antibody specifically binding to said actin or said RGD epitope

washing away unbound detectable wound targeting moiety from the wounded predetermined internal organ tissue after a predetermined incubation period;

detecting whether the detectable wound targeting moiety is specifically bound to the first exposed protein, peptide motif or epitope;

determining that the detectable wound targeting moiety does not bind appreciably above predetermined background levels to unwounded tissue;

identifying the first exposed protein, peptide motif or epitope specifically bound to the first detectable wound targeting moiety as a first wound target;

identifying an amino acid sequence of the identified first exposed protein, peptide motif or epitope and selecting a second protein, peptide motif or epitope having a similar amino acid sequence to the first protein, peptide motif or epitope as a candidate wound target and performing the incubating, washing, detecting and determining steps above to confirm the second protein, peptide motif or epitope as a second wound target.

7. The method of claim 6 , wherein the first preselected detectable wound targeting moiety is a detectable antibody specific for the actin.

8. The method of claim 1 , wherein the exposed protein, peptide motif or epitope is a cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Jan 17, 2020
From: CITIBANK, N.A., AS COLLATERAL AGENT
To: LEIDOS, INC.
Reel/Frame 051632/0819 →
RELEASE OF SECURITY INTEREST Recorded Jan 17, 2020
From: CITIBANK, N.A., AS COLLATERAL AGENT
To: LEIDOS, INC.
Reel/Frame 051632/0742 →
SECURITY INTEREST Recorded Aug 25, 2016
From: LEIDOS, INC.
To: CITIBANK, N.A.
Reel/Frame 039809/0801 →
SECURITY INTEREST Recorded Aug 25, 2016
From: LEIDOS, INC.
To: CITIBANK, N.A.
Reel/Frame 039818/0272 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2016
From: GRIFFEY, RICHARD HOLMES
To: SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
Reel/Frame 039001/0702 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2016
From: DRESIOS, JOHN
To: SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
Reel/Frame 039001/0673 →
CHANGE OF NAME Recorded Jun 24, 2016
From: SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
To: LEIDOS, INC.
Reel/Frame 039154/0689 →
Continuity (6)
Division 14934425 · Nov 6, 2015
Division 14158775 · Jan 17, 2014
Division 13332738 · Dec 21, 2011
Provisional Application 61426882 · Dec 23, 2010
Provisional Application 61425491 · Dec 21, 2010
Related Publication 20170089922A1 · Mar 30, 2017